No Data
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $22
Piper Sandler analyst Allison Bratzel maintains $Roivant Sciences(ROIV.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 62.1%
Roivant Sciences Price Target Raised to $22.00/Share From $20.00 by Piper Sandler
Roivant Sciences Price Target Raised to $22.00/Share From $20.00 by Piper
Roivant Sciences Is Maintained at Overweight by Piper Sandler
Roivant Sciences Is Maintained at Overweight by Piper
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $22
Piper Sandler analyst Allison Bratzel maintains $Roivant Sciences(ROIV.US)$ with a buy rating, and adjusts the target price from $20 to $22.According to TipRanks data, the analyst has a success rate
Express News | Roivant Sciences Ltd : Piper Sandler Raises Target Price to $22 From $20
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Roivant Sciences (NASDAQ:ROIV) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a concise overview o